Hydroxyzine Market Size & Share 2024 – 2032

Hydroxyzine Market Size

Hydroxyzine Market size was valued at around USD 784.4 million in 2023 and is estimated to grow at 5.4% CAGR from 2024 to 2032. Hydroxyzine is a medication primarily used to treat itching caused by allergies. It belongs to a class of drugs known as antihistamines, which work by blocking the effects of histamine, a substance in the body that causes allergic symptoms.

Allergies are becoming more prevalent globally, with a rising number of individuals experiencing allergic reactions to various triggers such as pollen, dust, food, and insect bites. Hydroxyzine, as an antihistamine, is commonly prescribed to alleviate symptoms such as itching, hives, and rashes associated with allergies. The growing incidence of allergic reactions is stimulating the demand for medications such as hydroxyzine.
 

Further, pharmaceutical companies are continually investing in research and development to enhance existing medications and develop new therapeutic options. This includes efforts to improve the efficacy, safety, and delivery mechanisms of antihistamines such as hydroxyzine.

 

Hydroxyzine Market Trends

Technological innovations in pharmaceutical drug delivery, which is estimated to reach USD 3.2 trillion by 2032, have led to the development of novel formulations of hydroxyzine, such as extended-release tablets, oral solutions, and intramuscular injections. These advancements offer advantages such as improved bioavailability, better patient compliance, and reduced side effects. For instance, long-acting formulations of hydroxyzine provide sustained relief from allergic symptoms, thereby enhancing patient convenience and treatment outcomes.
 

• Hydroxyzine is not only used to treat allergies but also finds applications in other medical conditions such as anxiety, and tension caused by nervous and emotional conditions. Thus, as awareness grows regarding its effectiveness in managing these conditions, the demand for hydroxyzine is likely to increase.
   

Hydroxyzine Market Analysis

Based on dosage form, the market is divided into tablets, capsules, injections, and syrups. The tablets segment of the hydroxyzine industry is forecast to reach USD 557.1 million by 2032, highlighting robust growth propelled by several key factors.
 

• Tablets offer convenience and ease of administration, making them a preferred choice for both healthcare providers and patients alike. With tablets, precise dosages can be easily administered, ensuring effective treatment outcomes while simplifying medication management for individuals.
   
• Advancements in pharmaceutical formulation technologies have enhanced the bioavailability and efficacy of hydroxyzine tablets, further driving their adoption in clinical settings. These innovations have facilitated the development of extended-release formulations, enabling sustained drug release and improved patient compliance.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on route of administration, the hydroxyzine market is bifurcated into oral, and intramuscular. The oral segment accounted for USD 628 million in 2023.
 

• This dominance stems from various factors, including patient convenience, ease of administration, and patient preference. Oral administration offers a straightforward and convenient option for patients, requiring no specialized training or equipment.
   
• It provides flexibility in dosing, reduces the risk of complications associated with other routes, and is cost-effective compared to intramuscular injections.
   
• Additionally, oral medications are widely accessible, contributing to their widespread use and market dominance in hydroxyzine treatment.
   

Based on indication, the market is bifurcated into histamine-mediated pruritus, atopic contact dermatitis, and urticaria. The histamine-mediated pruritus segment accounted for USD 376.4 million in 2023.
 

• Histamine-mediated pruritus, a common condition associated with allergic reactions, affects a significant portion of the population, stimulating the demand for effective treatments such as hydroxyzine.
   
• Further, hydroxyzine's established efficacy in managing pruritus, coupled with its safety profile, makes it a preferred choice among physicians as a first-line treatment. Moreover, patients seeking relief from itching and discomfort are drawn to hydroxyzine due to its quick and effective relief.
   

Based on distribution channel, the hydroxyzine industry is bifurcated into hospital pharmacies, online pharmacies, and retail pharmacies. The hospital pharmacies segment accounted for USD 391.2 million in 2023.
 

• Hospital pharmacies often serve as the primary source of medications for inpatients and outpatients alike, making them a key distribution channel for hydroxyzine, especially in acute care settings where patients may require immediate relief from symptoms such as itching.
   
• Further, healthcare professionals in hospital settings, including physicians and pharmacists, frequently prescribe and dispense hydroxyzine to patients with various conditions, including allergic reactions and pruritus, further driving demand within this segment.
   
• Additionally, the ability of hospital pharmacies to procure and stock a wide range of pharmaceutical products, including hydroxyzine, ensures accessibility and availability for patients receiving treatment in hospital settings.
   

The hydroxyzine market in U.S. accounted for a significant revenue of USD 290 million in 2023, and this trajectory is set to continue upwards.
 

• Continuous innovation by pharmaceutical companies in the country results in the introduction of new hydroxyzine formulations such as extended-release tablets or combination medications. These developments enhance the drug's effectiveness and patient adherence, thereby broadening the market with diverse treatment options that cater to individual patient requirements.
   

The market in Germany is expected to experience significant and promising growth from 2024 to 2032.
 

• Germany boasts a robust healthcare infrastructure with a strong emphasis on research and development. This supportive environment fosters innovation in pharmaceuticals and facilitates the introduction of new drugs to the market. With ongoing advancements, the accessibility and availability of hydroxyzine are expected to increase, further fueling market growth.
   

Japan market is anticipated to witness lucrative growth between 2024 – 2032.
 

• Japan has a rapidly aging population, leading to an increased prevalence of age-related health conditions such as anxiety disorders and allergic reactions. Therefore, as a result, there will likely be a higher demand for medications such as hydroxyzine to manage these conditions among the elderly.
   

The hydroxyzine industry in Saudi Arabia is expected to experience significant and promising growth from 2024 to 2032.
 

• Saudi Arabia has been actively fostering its pharmaceutical industry, aiming for self-sufficiency, and reducing reliance on imports. This push towards domestic production and innovation could lead to increased production capacities for medications such as hydroxyzine, thereby meeting the growing demand within the country and potentially even exporting to neighboring regions.
   

Hydroxyzine Market Share

The hydroxyzine sector is competitive in nature, with a mix of major global and smaller to medium-sized companies competing for market share. A pivotal aspect of market strategy involves the continual introduction of innovative products leveraging diverse technologies. Notably, prominent industry players command significant influence in this dynamic landscape, often driving forward advancements through substantial investments in research and development. Additionally, strategic alliances, acquisitions, and mergers are instrumental in fortifying market positions and expanding global footprint amidst evolving regulatory landscapes.
 

Hydroxyzine Market Companies

Some of the eminent market participants operating in the hydroxyzine industry include:

• Alliance Pharma Plc
• Amneal Pharmaceuticals, Inc.
• Aurobindo Pharma Limited
• Glenmark Pharmaceuticals Ltd.
• MYLAN N.V.
• Novartis AG
• Pfizer Inc.
• Piramal Enterprises Limited
• Sun Pharmaceutical Industries Limited
• Teva Pharmaceutical Industries Limited
   

Hydroxyzine Industry News:

• In April 2022, Aurobindo Pharma Ltd acquired the domestic formulation business of Veritaz, which served as a valuable launch pad for marketing biosimilar and other pharmaceutical products in India. This acquisition expanded the company's geographical footprint within India.
   

The hydroxyzine market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Dosage Form

• Tablets
• Capsules
• Injections
• Syrups

Market, Route of Administration

• Oral
• Intramuscular

Market, By Indication

• Histamine-mediated pruritus
• Urticaria
• Atopic contact dermatitis

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe 
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific 
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America 
• Middle East and Africa 
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa